nach oben

European Journal of Nutrition

Erschienen in:

01.04.2012 | Original Contribution

Bovine lactoferrin induces interleukin-11 production in a hepatitis mouse model and human intestinal myofibroblasts

verfasst von: Tetsuya Kuhara, Koji Yamauchi, Keiji Iwatsuki

Erschienen in: European Journal of Nutrition | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Orally administered bovine lactoferrin (bLF) exerts an anti-inflammatory effect on hepatitis and colitis animal models. To investigate the mechanism underlying the action of bLF, we explored the expression of inflammation-related factors in the intestine of a hepatitis mouse model after the oral administration of bLF and in several human intestinal cell lines treated with bLF.

Methods

The effects of bLF on the expression of interleukin-11 (IL-11) and bone morphogenetic protein 2 (BMP2) in the intestinal mucosa of a hepatitis mouse model as well as in cell cultures of human intestinal epithelial cells, myofibroblasts, and monocytes were examined using the real-time reverse transcription polymerase chain reaction. Epithelial cells and myofibroblasts were also cocultured using transwells. bLF transport, and IL-11 and BMP2 induction, as well as the interactions between the two cell types, were then analyzed after bLF treatment.

Results

In vivo, oral bLF administration increased the production of IL-11 and BMP2 in intestinal specimens. In vitro, bLF only stimulated the production of IL-11 in human intestinal myofibroblasts; i.e., it had no effect on BMP2 production in any cell type. In the transwell cocultures, bLF passed through the epithelium and directly stimulated IL-11 production in the myofibroblasts on the basolateral side. The IL-11 produced in the myofibroblasts subsequently acted protectively on the epithelial cells of the coculture.

Conclusions

bLF upregulated the activity of anti-inflammatory factors, such as IL-11, in the intestine of a hepatitis mouse model and human intestinal myofibroblasts.

Brock JH (2002) The physiology of lactoferrin. Biochem Cell Biol 80:1–6CrossRef

Lönnerdal B (2009) Nutritional roles of lactoferrin. Curr Opin Clin Nutr Metab Care 12:293–297CrossRef

Tanaka K, Ikeda M, Nozaki A et al (1999) Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn J Cancer Res 90:367–371CrossRef

Iwasa M, Kaito M, Ikoma J et al (2002) Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. Am J Gastroenterol 97:766–767CrossRef

Okada S, Tanaka K, Sato T et al (2002) Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res 93:1063–1069CrossRef

Konishi M, Iwasa M, Yamauchi K et al (2006) Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol Res 36:27–32CrossRef

Yamauchi K, Hiruma M, Yamazaki N et al (2000) Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study. Mycoses 43:197–202CrossRef

Kozu T, Iinuma G, Ohashi Y et al (2009) Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res 2:975–983CrossRef

Kuwata H, Yamauchi K, Teraguchi S et al (2001) Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats. J Nutr 131:2121–2127

10.

Togawa J, Nagase H, Tanaka K et al (2002) Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol 283:G187–G195

11.

Tsubota A, Yoshikawa T, Nariai K et al (2008) Bovine lactoferrin potently inhibits liver mitochondrial 8-OHdG levels and retrieves hepatic OGG1 activities in long-evans Cinnamon rats. J Hepatol 48:486–493CrossRef

12.

Horiuchi Y, Higuchi T, Tatsumi K et al (2009) Lactoferrin is associated with a decrease in oocyte depletion in mice receiving cyclophosphamide. Fertil Steril 91:2069–2078CrossRef

13.

Kuhara T, Yamauchi K, Tamura Y et al (2006) Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interf Cytok Res 26:489–499CrossRef

14.

Kuhara T, Iigo M, Itoh T et al (2000) Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 38:192–199CrossRef

15.

Du X, Williams DA (1997) Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89:3897–3908

16.

Trepicchio WL, Wang L, Bozza M et al (1997) IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol 159:5661–5670

17.

Ropeleski MJ, Tang J, Walsh-Reitz MM et al (2003) Interleukin-11-induced heat shock protein 25 confers intestinal epithelial-specific cytoprotection from oxidant stress. Gastroenterology 124:1358–1368CrossRef

18.

Ellis M, Zwaan F, Hedström U et al (2003) Recombinant human interleukin 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomized trial. Lancet 361:275–280CrossRef

19.

Sands BE, Bank S, Sninsky CA et al (1999) Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn’s disease. Gastroenterology 117:58–64CrossRef

20.

Sands BE, Winston BD, Salzberg B et al (2002) Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease. Aliment Pharmacol Ther 16:399–406CrossRef

21.

Lawitz EJ, Hepburn MJ, Casey TJ (2004) A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol 99:2359–2364CrossRef

22.

Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22:233–241CrossRef

23.

Hardwick JC, Van Den Brink GR, Bleuming SA et al (2004) Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 126:111–121CrossRef

24.

Nakatsuka R, Taniguchi M, Hirata M et al (2007) Transient expression of bone morphogenetic protein-2 in acute liver injury by carbon tetrachloride. J Biochem 141:113–119CrossRef

25.

Yamaguchi M, Matsuura M, Kobayashi K et al (2001) Lactoferrin protects against development of hepatitis caused by sensitization of Kupffer cells by lipopolysaccharide. Clin Diagn Lab Immunol 8:1234–1239

26.

Blais A, Malet A, Mikogami T et al (2009) Oral bovine lactoferrin improves bone status of ovariectomizes mice. Am J Physiol Endocrinol Metab 296:E1281–E1288CrossRef

27.

Powell DW, Mifflin RC, Valentich JD et al (1999) Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 277:C183–C201

28.

Mikogami T, Heyman M, Spik G et al (1994) Apical-to-basolateral transepithelial transport of human lactoferrin in the intestinal cell line HT-29 cl.19A. Am J Physiol 267:G308–G315

29.

Trepicchio WL, Ozawa M, Walters IB et al (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104:1527–1537CrossRef

30.

Manzoni P, Rinaldi M, Cattani S et al (2009) Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 302:1421–1428CrossRef

31.

Qiu BS, Pfeiffer CJ, Keith JC Jr (1996) Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 41:1625–1630CrossRef

32.

Bozza M, Bliss JL, Maylor R et al (1990) Interleukin-11 reduces T-cell-dependent experimental liver injury in mice. Hepatology 30:1441–1447CrossRef

33.

Hori M, Sawai H, Tsuji Y et al (2006) Bone morphogenetic protein-2 counterregulates interleukin-18 mRNA and protein in MC3T3–E1 mouse osteoblastic cells. Connect Tissue Res 47:124–132CrossRef

Titel: Bovine lactoferrin induces interleukin-11 production in a hepatitis mouse model and human intestinal myofibroblasts
verfasst von: Tetsuya Kuhara
Koji Yamauchi
Keiji Iwatsuki
Publikationsdatum: 01.04.2012
Verlag: Springer-Verlag
Erschienen in: European Journal of Nutrition / Ausgabe 3/2012
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-011-0219-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

A gluten metabolism study in healthy individuals shows the presence of faecal glutenasic activity

The immunomodulatory properties of viable Lactobacillus salivarius ssp. salivarius CECT5713 are not restricted to the large intestine

Major dietary patterns and cardiovascular risk factors among young Brazilian adults

Differential effects of 1α,25-dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes

S-allylmercaptocysteine reduces carbon tetrachloride-induced hepatic oxidative stress and necroinflammation via nuclear factor kappa B-dependent pathways in mice